BACKGROUND/AIM: Magnetic resonance imaging (MRI), cerebral blood flow single photon emission computed tomography (CBF-SPECT), fluorodeoxyglucose-positron emission tomography (FDG-PET) and cerebrospinal fluid (CSF) biomarkers are used for the diagnosis of Alzheimer's disease (AD). We aimed to reveal the relative sensitivity of these tools in a memory clinic setting. METHODS: In 207 patients with probable AD in our memory clinic, medial temporal lobe atrophy on MRI, hypoperfusion/hypometabolism of the parietotemporal lobe and posterior cingulate gyrus in ethylcysteinate dimer-CBF-SPECT/FDG-PET, and abnormalities of CSF amyloid β-protein 1-42, total tau and phosphorylated tau were evaluated as findings characteristic of AD. RESULTS: The AD findings were observed in 77.4% of all AD patients with MRI, 81.6% with CBF-SPECT, 93.1% with FDG-PET and 94.0% with CSF biomarkers. At the stage of Clinical Dementia Rating (CDR) 0.5, CSF biomarkers were the most sensitive (90.0%); at the stage of CDR 1, FDG-PET (96.7%) and CSF biomarkers (95.5%) were highly sensitive. At the stage of CDR 2, all tools showed high positive percentages. CONCLUSION: The diagnosis of AD was most often supported by CSF biomarkers and FDG-PET at the early stage of dementia (CDR 1) and by CSF biomarkers at the earlier stage (CDR 0.5).
BACKGROUND/AIM: Magnetic resonance imaging (MRI), cerebral blood flow single photon emission computed tomography (CBF-SPECT), fluorodeoxyglucose-positron emission tomography (FDG-PET) and cerebrospinal fluid (CSF) biomarkers are used for the diagnosis of Alzheimer's disease (AD). We aimed to reveal the relative sensitivity of these tools in a memory clinic setting. METHODS: In 207 patients with probable AD in our memory clinic, medial temporal lobe atrophy on MRI, hypoperfusion/hypometabolism of the parietotemporal lobe and posterior cingulate gyrus in ethylcysteinate dimer-CBF-SPECT/FDG-PET, and abnormalities of CSF amyloid β-protein 1-42, total tau and phosphorylated tau were evaluated as findings characteristic of AD. RESULTS: The AD findings were observed in 77.4% of all ADpatients with MRI, 81.6% with CBF-SPECT, 93.1% with FDG-PET and 94.0% with CSF biomarkers. At the stage of Clinical Dementia Rating (CDR) 0.5, CSF biomarkers were the most sensitive (90.0%); at the stage of CDR 1, FDG-PET (96.7%) and CSF biomarkers (95.5%) were highly sensitive. At the stage of CDR 2, all tools showed high positive percentages. CONCLUSION: The diagnosis of AD was most often supported by CSF biomarkers and FDG-PET at the early stage of dementia (CDR 1) and by CSF biomarkers at the earlier stage (CDR 0.5).
Authors: Annapaola Prestia; Anna Caroli; Karl Herholz; Eric Reiman; Kewei Chen; William J Jagust; Giovanni B Frisoni Journal: Alzheimers Dement Date: 2013-01-30 Impact factor: 21.566
Authors: Giovanni B Frisoni; Martina Bocchetta; Gael Chételat; Gil D Rabinovici; Mony J de Leon; Jeffrey Kaye; Eric M Reiman; Philip Scheltens; Frederik Barkhof; Sandra E Black; David J Brooks; Maria C Carrillo; Nick C Fox; Karl Herholz; Agneta Nordberg; Clifford R Jack; William J Jagust; Keith A Johnson; Christopher C Rowe; Reisa A Sperling; William Thies; Lars-Olof Wahlund; Michael W Weiner; Patrizio Pasqualetti; Charles Decarli Journal: Neurology Date: 2013-07-30 Impact factor: 9.910
Authors: Christian Habeck; Shannon Risacher; Grace J Lee; M Maria Glymour; Elizabeth Mormino; Shubhabrata Mukherjee; Sungeun Kim; Kwangsik Nho; Charles DeCarli; Andrew J Saykin; Paul K Crane Journal: Brain Imaging Behav Date: 2012-12 Impact factor: 3.978